Anika Therapeutics, Inc. revised revenue guidance for the fiscal year 2023. For the year, the company raised its overall revenue outlook to be between $164 million to $166 million, representing growth of 5% to 6% compared to 2022, up from its previous range of $159.5 million to $163 million.